Anti-interleukin-12 and anti-interleukin-23 agents in Crohn’s disease

Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

(2018) W. J. Sandborn et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

882 - Efficacy and Safety of Anti-Interleukin-23 Therapy with Mirikizumab (LY3074828) in Patients with Moderate-To-Severe Ulcerative Colitis in a Phase 2 Study

(2018) William J. Sandborn et al.   GASTROENTEROLOGY

Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease

(2018) Omoniyi J. Adedokun et al.   GASTROENTEROLOGY

Selective IL-23 inhibition by risankizumab modulates the molecular profile in the colon and ileum of patients with active Crohn’s disease: Results from a randomised phase II biopsy substudy

(2018) Sudha Visvanathan et al.   Journal of Crohns & Colitis

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study

(2017) Bruce E. Sands et al.   GASTROENTEROLOGY

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

(2017) Brian G Feagan et al.   LANCET

Ustekinumab use in Crohn’s disease: a Canadian tertiary care centre experience

(2017) Astrid-Jane Greenup et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents

(2016) Pauline Wils et al.   Clinical Gastroenterology and Hepatology

Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease

(2016) Alessandro Armuzzi et al.   DIGESTIVE AND LIVER DISEASE

Next generation of small molecules in inflammatory bowel disease

(2016) Pablo Olivera et al.   GUT

Patients with Refractory Crohnʼs Disease Successfully Treated with Ustekinumab

(2016) Kimberly A. Harris et al.   INFLAMMATORY BOWEL DISEASES

Ustekinumab for the Treatment of Refractory Crohnʼs Disease

(2016) Sam Khorrami et al.   INFLAMMATORY BOWEL DISEASES

Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

(2016) A. Menter et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

(2015) L Peyrin-Biroulet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up

(2015) R.G. Langley et al.   BRITISH JOURNAL OF DERMATOLOGY

Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis

(2015) Glen S. Hazlewood et al.   GASTROENTEROLOGY

Biologics in inflammatory bowel disease: what are the data?

(2015) Justin Côté-Daigneault et al.   United European Gastroenterology Journal

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

(2014) Christopher Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-12-and IL-23 in health and disease

(2014) Andrew L. Croxford et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—The McGill experience

(2014) U. Kopylov et al.   Journal of Crohns & Colitis

Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis

(2014) Mitsuha Hayashi et al.   JOURNAL OF DERMATOLOGY

Tumor Necrosis Factor Alpha Blocking Agents as Treatment for Ulcerative Colitis Intolerant or Refractory to Conventional Medical Therapy: A Meta-Analysis

(2014) Ruxi Lv et al.   PLoS One

Role of the gut microbiota in inflammatory bowel disease pathogenesis: What have we learnt in the past 10 years?

(2014) Georgina L Hold   WORLD JOURNAL OF GASTROENTEROLOGY

Paradoxical effects of anti-TNF-α agents in inflammatory diseases

(2013) Daniel Wendling et al.   Expert Review of Clinical Immunology

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Pooled Analysis of Infections, Malignancy and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease

(2012) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

(2012) A.B. Kimball et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Review article: loss of response to anti-TNF treatments in Crohn’s disease

(2011) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease

(2011) Alessandra Geremia et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity

(2011) Z. Liu et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials

(2011) Mark Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials

(2011) Kenneth B. Gordon et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease

(2010) Mario Cottone et al.   Clinical Gastroenterology and Hepatology

The use of ustekinumab in autoimmune disease

(2010) Caitriona Ryan et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Cytokine Requirements for the Differentiation and Expansion of IL-17A- and IL-22-Producing Human V 2V 2 T Cells

(2010) K. J. Ness-Schwickerath et al.   JOURNAL OF IMMUNOLOGY

Diverse Genome-wide Association Studies Associate the IL12/IL23 Pathway with Crohn Disease

(2009) Kai Wang et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Inflammatory Bowel Disease

(2009) Clara Abraham et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

IL-23 modulates CD56+/CD3- NK Cell and CD56+/CD3+ NK-like T Cell function differentially from IL-12

(2008) D. van de Wetering et al.   INTERNATIONAL IMMUNOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET